Femasys is trading at $1.75, up 11.86%; biotech strength offers context, but no company-specific announcement clearly explains the gain. - On October 14, Femasys announced it doubled active enrollment sites in the FemBloc FINALE pivotal trial to twelve, but coverage does not establish that this drove the October 15 move. - The sector update showed XBI up 2.20%, alongside positive clinical and regulatory news elsewhere in biotech; this supports sector context, not a confirmed Femasys-specific catalyst.